Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Zytronic PLC, a publicly-traded company, has announced that it will not be able to publish its Annual Report & Accounts for the fiscal year ending September 30, 2024 (FY24 AR&A) by the deadline of March 31, 2025. As a result, trading in the Company’s shares on the Alternative Investment Market (AIM) will be suspended starting April 1, 2025.
The delay comes after the Board’s decision on February 26, 2025, to wind down the company, which necessitated a shift in the preparation of the accounts. The financial statements are being audited on a non-going concern basis, which has extended the time needed to finalize the report.
Zytronic is actively working with its advisers to release a shareholder circular within the week starting March 31, 2025. This document will provide details on the proposed cancellation of the Company’s listing on AIM and plans to re-register Zytronic as a private limited company.
The Board has indicated that it does not expect the FY24 AR&A to be published before the proposed cancellation date. If shareholders pass the necessary resolutions, the last day of trading Zytronic shares on AIM will be March 31, 2025.
This update follows the Company’s previous announcement on February 26, 2025, which included an outcome statement from FRP Advisory. The statement is part of the ongoing communications to shareholders about the Company’s financial status and future plans.
The information in this article is based on a press release statement from Zytronic PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.